NASDAQ · CLNN
Clene Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CLNN: Nov 12, 2026
Clene Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.46. The reported EPS for the same quarter last year was $-0.85.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.46 | $-0.43 | $-0.48 | 2 |
| Dec 2026 | $-0.41 | $-0.41 | $-0.42 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks- RTTNews · Oct 21, 5:59 AM EDTWill Clene's Gold Nanocrystal Therapy Earn A Place In The ALS Treatment Arsenal?(RTTNews) – Neuronal decline is a natural part of ageing. In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), this decline is accelerated and compounded by energy deficits, which contribute to neuronal dysfunction and ultimately cell death. An estimated 35
- RTTNews · Oct 19, 11:05 AM EDTClene Seeks FDA Clearance For CNM-Au8 Following ALS Clinical Research(RTTNews) – Clene Inc. (CLNN), a clinical-stage biopharmaceutical company, announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) earlier in October, seeking accelerated approval of CNM-Au8 for the treatment of amyotrophic lateral
- MarketBeat · Oct 2, 8:02 AM EDTClene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 DecisionClene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS. In a fireside chat at the Lytham Partners Fall
- RTTNews · Sep 15, 2:43 PM EDTBiotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers(RTTNews) – Several biotech stocks were in focus Tuesday, including PDS Biotech following a potential $22.55 million PIPE financing; Avaí Bio after completing testing of its GMP Master Cell Bank; Clene following a $4 million registered direct offering; NurExone after entering an
- RTTNews · Sep 15, 9:14 AM EDTClene Announces $4M Registered Direct Offering; Funding Expected Through Q1 2027(RTTNews) – Clene Inc. (CLNN), a clinical-stage biotechnology company focused on ALS and other neurodegenerative diseases, announced the pricing of a $4 million registered direct offering of 1,219,513 shares at $3.28 per share.
- MarketBeat · Aug 19, 6:03 PM EDTClene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker AnalysesClene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington
- Zacks · Aug 14, 9:20 AM EDTClene Inc. (CLNN) Reports Q2 Loss, Beats Revenue EstimatesClene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Aug 12, 6:02 AM EDTClene Targets Early Q4 NDA Filing for CNM-Au8 in ALSClene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration. President and CEO Rob Eth
- Zacks · Aug 11, 10:25 AM EDTMicrobot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue EstimatesMicrobot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 5:40 PM EDTLineage Cell (LCTX) Reports Q2 Loss, Lags Revenue EstimatesLineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and -80.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jun 18, 9:40 AM EDTAre Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
- Zacks · Jun 4, 9:55 AM EDTClene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowClene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround i
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Clene Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.